Crossmark

First-line Polatuzumab vedotin plus R-CHP in primary mediastinal B-cell lymphoma: A real-world study bridging the gap of the POLARIX trial

Published Online: 2026-04-22

Authors

Yang, Xue

Ren, Yuhong

Cheng, Luya

Liu, Yalan

Yao, Jiamei

Tan, Hui

Liu, Peng
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82200176)

Natural Science Foundation of Shanghai (22ZR1411400)
License Information

Text and Data Mining valid from 2026-04-22

Version of Record valid from 2026-04-22
More Information

Article History

Received: 23 January 2026

Accepted: 17 April 2026

First Online: 22 April 2026

Declarations

:

: This study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University in accordance with Declaration of Helsinki (Approval No. B2023-184). All patients signed informed consents.

: The study obtained written informed consent from all patients.

: The authors declare no competing interests.

Document is current